ASTX295, identified by its CAS number 2093449-12-6, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is characterized as a small molecule with a specific structure that allows it to interact with biological targets, often related to the modulation of immune responses. The compound is typically evaluated for its efficacy, safety, and mechanism of action in preclinical and clinical studies. Its solubility, stability, and bioavailability are critical factors that influence its pharmacokinetic properties. Additionally, ASTX295 may exhibit specific interactions with proteins or enzymes, which can be explored through various biochemical assays. As research progresses, the compound's characteristics, including its potential side effects and therapeutic window, will be further elucidated, contributing to the understanding of its role in treating specific diseases or conditions. Overall, ASTX295 represents a promising candidate in the field of medicinal chemistry and drug development.

ASTX295

2093449-12-6: ASTX295, identified by its CAS number 2093449-12-6, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. It is characterized as a small molecule with a specific structure that allows it to interact with biological targets, often related to the modulation of immune responses. The compound is typically evaluated for its efficacy, safety, and mechanism of action in preclinical and clinical studies. Its solubility, stability, and bioavailability are critical factors that influence its pharmacokinetic properties. Additionally, ASTX295 may exhibit specific interactions with proteins or enzymes, which can be explored through various biochemical assays. As research progresses, the compound's characteristics, including its potential side effects and therapeutic window, will be further elucidated, contributing to the understanding of its role in treating specific diseases or conditions. Overall, ASTX295 represents a promising candidate in the field of medicinal chemistry and drug development.

<p>ASTX295 is a selective mouse double minute 2 (MDM2) antagonist with an IC50 value of less than 1 nM. It specifically inhibits the interaction between MDM2 and p53, reactivating wild-type (WT) TP53, which subsequently induces the expression of related transcriptional targets, leading to cell death and cell cycle arrest. ASTX295 holds potential for research in lymphoid malignancies such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and T-cell lymphoma.</p>

CAS 2093449-12-6

ASTX295

ASTX295

Ref: TM-T206682